JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB257049

Human SMAD4 knockout HeLa cell lysate

Be the first to review this product! Submit a review

|

(0 Publication)

Human SMAD4 knockout HeLa cell lysate. View our extensive range of validated lysates from normal and diseased human, mouse and rat tissue.

View Alternative Names

(Small) Mothers Against Decapentaplegic, DPC 4, Deleted in Pancreatic Carcinoma, Deleted in Pancreatic Carcinoma 4, Deleted in pancreatic carcinoma locus 4, Deletion target in pancreatic carcinoma 4, JIP, MAD homolog 4, MAD mothers against decapentaplegic Drosophila homolog 4, MAD mothers against decapentaplegic homolog 4, MADH 4, MED, MYHRS, Medea, Mothers against DPP homolog 4, Mothers against decapentaplegic homolog 4, Mothers against decapentaplegic, Drosophila, homolog of, 4, OTTHUMP00000163548, SMA- and MAD-related protein 4, SMAD family member 4, SMAD mothers against DPP homolog 4, SMAD4_HUMAN, hSMAD4

1 Images
Sanger Sequencing - Human SMAD4 knockout HeLa cell lysate (AB257049)
  • Sanger seq

Unknown

Sanger Sequencing - Human SMAD4 knockout HeLa cell lysate (AB257049)

Homozygous : 5 bp deletion in exon5

Key facts

Cell type

HeLa

Species or organism

Human

Tissue

Cervix

Knockout validation

Sanger Sequencing

Mutation description

Knockout achieved by using CRISPR/Cas9, 5 bp deletion in exon5.

Disease

Adenocarcinoma

style
left-column
style
left-column

Product details

Knockout cell lysate achieved by CRISPR/Cas9.

REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.

Lysate preparation: Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10). This means that the protein of interest is denatured. If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.

User storage instructions: Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.

This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our limited use license and patent pages.

style
left-column

What's included?

{ "values": { "1Kit": { "sellingSize": "1 Kit", "publicAssetCode":"ab257049-1Kit", "assetComponentDetails": [ { "size":"1 x 100 µg", "name":"Human SMAD4 knockout HeLa cell lysate", "number":"AB257049-CMP02", "productcode":"" }, { "size":"1 x 100 µg", "name":"Human wild-type HeLa cell lysate", "number":"AB257049-CMP01", "productcode":"" } ] } } }
style
left-column

Properties and storage information

Gene name
SMAD4
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing
Shipped at conditions
Ambient - Can Ship with Ice
Appropriate short-term storage conditions
-20°C
Appropriate long-term storage conditions
-20°C
style
left-column

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

Smad4 also known as DPC4 or MADH4 is a central protein in the TGF-beta signaling pathway with a molecular mass of approximately 60 kDa. It acts as a signal transducer that facilitates communication from the cell surface to the nucleus. Smad4 is broadly expressed in various tissues playing an important role in the regulation of cellular processes. It forms a complex with receptor-regulated Smads (R-Smads) to translocate to the nucleus where it influences gene transcription.
Biological function summary

Smad4 influences cell proliferation differentiation and apoptosis by mediating signals from TGF-beta cytokines. It is part of the Smad protein family acting as a transcriptional controller. Upon TGF-beta receptor activation Smad4 forms complexes with Smad2 and Smad3 translocating to the nucleus to regulate genes imperative for cellular homeostasis. Its role in cell cycle regulation underlines its contribution to normal cellular functions and its potential involvement in disorders.

Pathways

Smad4 operates within the TGF-beta pathway linking extracellular signals to nuclear transcription alterations. It participates in the regulation of epithelial-mesenchymal transition (EMT) a process important for development and tumor progression. In these pathways Smad4 interacts closely with Smad2 and Smad3 orchestrating various cellular responses to external stimuli through transcriptional management.

Smad4 is highly related to cancer and juvenile polyposis syndrome. Mutations or deletions in Smad4 disrupt its function contributing to the progression of pancreatic cancer and colorectal cancer among others. Within these contexts Smad4 connects strongly to other proteins like p21 and cyclin-dependent kinase inhibitors which are important in cell cycle arrest and impede tumor growth.
style
left-column

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

style
left-column

Cell culture

Biosafety level

EU: 2 US: 2

Adherent/suspension

Adherent

Gender

Female

style
left-column

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:
style
left-column
style
left-column

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions
style
left-column
style
right-column
style
bg-slate-100

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com